Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Measures to mitigate disruption due to the COVID-19 pandemic of the MODIFY phase 3 pivotal trial in patients with Fabry disease

Autor: Frey, Aline, Trokan, Luba, Vogler, Markus, Hughes, Derralynn, Gimona, Alberto

Publikováno v: In Molecular Genetics and Metabolism February 2021 132(2):S39-S40

Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial.

Autor: Askanase AD; Columbia University Lupus Center, Division of Rheumatology, Columbia University College of Physicians & Surgeons, Columbia University, New York, NY, USA. Electronic address: ada20@cumc.columbia.edu., D'Cruz D; Department of Medicine, Guy's and St Thomas' Hospital, London, UK., Kalunian K; Department of Medicine, University of California, San Diego, San Diego, CA, USA., Merrill JT; Division of Rheumatology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA., Navarra SV; Clinical Projects, Arthritis and Clinical Immunology Program, University of Santo Tomas, Manila, Philippines., Cahuzac C; Data and Statistical Sciences Department, Hoffmann-La Roche Basel, Switzerland., Cornelisse P; Idorsia Pharmaceuticals, Allschwil, Switzerland., Murphy MJ; Idorsia Pharmaceuticals, Allschwil, Switzerland., Strasser DS; Idorsia Pharmaceuticals, Allschwil, Switzerland., Trokan L; Denali Therapeutics, San Francisco, CA, USA., Berkani O; Idorsia Pharmaceuticals, Allschwil, Switzerland.

Publikováno v: The Lancet. Rheumatology [Lancet Rheumatol] 2024 Nov 22. Date of Electronic Publication: 2024 Nov 22.